Brian Armstrong predicts New Limit will launch its first phase one clinical trial for epigenetic reprogramming in the next year (2027).
“We're now testing that in human primate, non human primates. Then the first phase one clinical trial we'll be launching next year.”
→ Read the source episode
Our resolution criterion
disputableNew Limit announces and initiates a phase one clinical trial for epigenetic reprogramming therapy in humans
More from No Priors: Artificial Intelligence | Technology | Startups
Renee Haas predicts that within 5+ years, chip design from idea to GDS2 file will be possible for certain designs, likely using AI tooling.
Renee Haas predicts that semiconductor supply chain constraints will persist for 3-5 years at minimum.
Max Hodak predicts that the next version of Prima will enter human trials within approximately one year and expand addressable patient population to millions
Max Hodak predicts that Cyens' in-house gene therapy will enter human trials within approximately one year
Max Hodak predicts that Cyens will make first commercial sales of Prima in Europe within weeks of July 2026
Eric Alabest predicts chess.com will launch additional games beyond chess and poker
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.